 BOSTON--BUSINESS WIRE--Verastem Oncology Nasdaq:VSTM, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of options to purchase 450,000 shares of its common stock and the grant of 150,000 restricted stock units RSUs to Louis J. Denis, MD, in connection with his appointment to Chief Medical Officer. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to Dr. Denis acceptance of 